ECOSPOR IV: An Open-Label Extension of Study SERES-012 and Open-Label Program for Evaluating SER-109 in Subjects With Recurrent Clostridioides Difficile Infection (RCDI)
Latest Information Update: 23 Aug 2024
Price :
$35 *
At a glance
- Drugs SER 109 (Primary)
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Acronyms ECOSPOR IV
- Sponsors Seres Therapeutics
- 12 Oct 2023 According to a Seres Therapeutics media release, results from post-hoc analysis of the ECOSPOR III and ECOSPOR IV Phase 3 studies will be presented at ID Week 2023
- 17 Jun 2023 According to a Seres Therapeutics media release, results from post-hoc analysis of the ECOSPOR III and ECOSPOR IV Phase 3 studies was featured as a late-breaker Emerging Science presentation at American Society of Microbiology (ASM) Microbe 2023
- 17 Jun 2023 Results from post-hoc analysis of the ECOSPOR III and ECOSPOR IV Phase 3 studies presented in the Seres Therapeutics Media Release